TY - JOUR
T1 - SARS-CoV-2 infection predisposes patients to coinfection with Staphylococcus aureus
AU - Lubkin, Ashira
AU - Bernard-Raichon, Lucie
AU - DuMont, Ashley L.
AU - Valero Jimenez, Ana Mayela
AU - Putzel, Gregory G.
AU - Gago, Juan
AU - Zwack, Erin E.
AU - Olusanya, Olufolakemi
AU - Boguslawski, Kristina M.
AU - Dallari, Simone
AU - Dyzenhaus, Sophie
AU - Herrmann, Christin
AU - Ilmain, Juliana K.
AU - Isom, Georgia L.
AU - Pawline, Miranda
AU - Perault, Andrew I.
AU - Perelman, Sofya
AU - Sause, William E.
AU - Shahi, Ifrah
AU - St John, Amelia
AU - Tierce, Rebecca
AU - Zheng, Xuhui
AU - Zhou, Chunyi
AU - Noval, Maria G.
AU - O'Keeffe, Anna
AU - Podkowik, Magda
AU - Gonzales, Sandra
AU - Inglima, Kenneth
AU - Desvignes, Ludovic
AU - Hochman, Sarah E.
AU - Stapleford, Kenneth A.
AU - Thorpe, Lorna E.
AU - Pironti, Alejandro
AU - Shopsin, Bo
AU - Cadwell, Ken
AU - Dittmann, Meike
AU - Torres, Victor J.
PY - 2024/8/14
Y1 - 2024/8/14
N2 - Severe COVID-19 has been associated with coinfections with bacterial and fungal pathogens. Notably, patients with COVID-19 who develop Staphylococcus aureus bacteremia exhibit higher rates of mortality than those infected with either pathogen alone. To understand this clinical scenario, we collected and examined S. aureus blood and respiratory isolates from a hospital in New York City during the early phase of the pandemic from both SARS-CoV-2+ and SARS-CoV-2- patients. Whole genome sequencing of these S. aureus isolates revealed broad phylogenetic diversity in both patient groups, suggesting that SARS-CoV-2 coinfection was not associated with a particular S. aureus lineage. Phenotypic characterization of the contemporary collection of S. aureus isolates from SARS-CoV-2+ and SARS-CoV-2- patients revealed no notable differences in several virulence traits examined. However, we noted a trend toward overrepresentation of S. aureus bloodstream strains with low cytotoxicity in the SARS-CoV-2+ group. We observed that patients coinfected with SARS-CoV-2 and S. aureus were more likely to die during the acute phase of infection when the coinfecting S. aureus strain exhibited high or low cytotoxicity. To further investigate the relationship between SARS-CoV-2 and S. aureus infections, we developed a murine coinfection model. These studies revealed that infection with SARS-CoV-2 renders mice susceptible to subsequent superinfection with low cytotoxicity S. aureus. Thus, SARS-CoV-2 infection sensitizes the host to coinfections, including S. aureus isolates with low intrinsic virulence. IMPORTANCE: The COVID-19 pandemic has had an enormous impact on healthcare across the globe. Patients who were severely infected with SARS-CoV-2, the virus causing COVID-19, sometimes became infected with other pathogens, which is termed coinfection. If the coinfecting pathogen is the bacterium Staphylococcus aureus, there is an increased risk of patient death. We collected S. aureus strains that coinfected patients with SARS-CoV-2 to study the disease outcome caused by the interaction of these two important pathogens. We found that both in patients and in mice, coinfection with an S. aureus strain lacking toxicity resulted in more severe disease during the early phase of infection, compared with infection with either pathogen alone. Thus, SARS-CoV-2 infection can directly increase the severity of S. aureus infection.
AB - Severe COVID-19 has been associated with coinfections with bacterial and fungal pathogens. Notably, patients with COVID-19 who develop Staphylococcus aureus bacteremia exhibit higher rates of mortality than those infected with either pathogen alone. To understand this clinical scenario, we collected and examined S. aureus blood and respiratory isolates from a hospital in New York City during the early phase of the pandemic from both SARS-CoV-2+ and SARS-CoV-2- patients. Whole genome sequencing of these S. aureus isolates revealed broad phylogenetic diversity in both patient groups, suggesting that SARS-CoV-2 coinfection was not associated with a particular S. aureus lineage. Phenotypic characterization of the contemporary collection of S. aureus isolates from SARS-CoV-2+ and SARS-CoV-2- patients revealed no notable differences in several virulence traits examined. However, we noted a trend toward overrepresentation of S. aureus bloodstream strains with low cytotoxicity in the SARS-CoV-2+ group. We observed that patients coinfected with SARS-CoV-2 and S. aureus were more likely to die during the acute phase of infection when the coinfecting S. aureus strain exhibited high or low cytotoxicity. To further investigate the relationship between SARS-CoV-2 and S. aureus infections, we developed a murine coinfection model. These studies revealed that infection with SARS-CoV-2 renders mice susceptible to subsequent superinfection with low cytotoxicity S. aureus. Thus, SARS-CoV-2 infection sensitizes the host to coinfections, including S. aureus isolates with low intrinsic virulence. IMPORTANCE: The COVID-19 pandemic has had an enormous impact on healthcare across the globe. Patients who were severely infected with SARS-CoV-2, the virus causing COVID-19, sometimes became infected with other pathogens, which is termed coinfection. If the coinfecting pathogen is the bacterium Staphylococcus aureus, there is an increased risk of patient death. We collected S. aureus strains that coinfected patients with SARS-CoV-2 to study the disease outcome caused by the interaction of these two important pathogens. We found that both in patients and in mice, coinfection with an S. aureus strain lacking toxicity resulted in more severe disease during the early phase of infection, compared with infection with either pathogen alone. Thus, SARS-CoV-2 infection can directly increase the severity of S. aureus infection.
KW - agr
KW - coinfection
KW - COVID
KW - MRSA
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85201326531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85201326531&partnerID=8YFLogxK
U2 - 10.1128/mbio.01667-24
DO - 10.1128/mbio.01667-24
M3 - Article
C2 - 39037272
AN - SCOPUS:85201326531
SN - 2161-2129
VL - 15
SP - e0166724
JO - mBio
JF - mBio
IS - 8
ER -